Try our Advanced Search for more refined results

Analysis

3 Places The Allergan Tribal Deal May Face Pushback

By Matthew Bultman ( October 12, 2017, 7:14 PM EDT) -- Allergan PLC's controversial attempt to shield patents for dry-eye drug Restasis from review at the Patent Trial and Appeal Board by making a deal with a Native American tribe has drawn intense scrutiny, amid concerns from groups including lawmakers and generic-drug companies. Here are three places where the deal will be closely examined....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Judge Analytics

powered by Lex Machina®

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!